U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. For Industry
  3. FDA User Fee Programs
  4. Prescription Drug User Fee Amendments
  5. Exhibit 2-2 long description
  1. Prescription Drug User Fee Amendments

Exhibit 2-2 long description

The major difference between the CMA Pilot 2 program and the Fast-Track program is the number of scheduled FDA/sponsor interactions. The Fast-Track program starts at the end-of-phase 1 (EOP1) meeting and generally has two other formal meetings scheduled, the EOP2 and the Pre-NDA/BLA meeting, with possible other informal meetings scheduled at random times. With CMA Pilot 2, in addition to the landmark meetings mentioned for the Fast-Track program, there are other planned meetings including a Preclinical-ADME plan, CMC-stability, CMC-validation plan, Clinical-Phase1/Phase 2 results, Clinical-Preliminary Phase 3 analysis, CMC-Phase 3 results and CMC-PAI plan. Also there is guaranteed FDA feedback within an agreed to time frame in the CMA Pilot 2 program.

Back to Top